This study is a randomised controlled trial evaluating ONERO™. This is a High-intensity Resistance and Impact Training (HiRIT) exercise intervention that has potential benefits for bone health and muscle strength in people with (MS). Qualified physiotherapists will supervise balance exercises, impact movements and weightlifting in twice-weekly, 45-minute sessions. Participation involves a total of 24 months. For the first 12 months, participants in the intervention group will attend the ONERO™ program (at no cost), and participants in the control group will attend usual healthcare. This is followed by a 12-month period where all participants will be offered to attend the ONERO™ program (no cost for control group; cost covered by NDIS for intervention group). This research aims to determine if the program is feasible, acceptable, and effective in improving bone mineral density, muscle strength, physical function, quality of life and mood.

• Aged 30 years or older.
• Medically confirmed diagnosis of multiple sclerosis (any subtype).
• Able to weight bear independently for at least 10 minutes.
• Able to perform basic functional movements (e.g., sit-to-stand without hands, pick up a basket, reach overhead).
• Willing to attend supervised, on-site exercise sessions twice weekly for 12 months.
• Able to undertake at least three of the four core resistance exercises (potentially with modification).
• Proficient in English.
• Able to provide informed consent and follow exercise instructions.

• Diagnosis of Clinically Isolated Syndrome (CIS) only (not confirmed MS).
• Presence of a comorbid neurological condition.
• Cognitive or psychological difficulties that would prevent safe participation or following instructions.
• Unable to attend one of the designated intervention sites.
• Sustained a bone fracture within the previous 3 months.
• A T-score of -3.0 or lower.

Trial has commenced recruitment

Dr Lisa Grech, Senior Research Fellow, Deakin University

Email: l.grech@deakin.edu.au

Full details of the trial can be found on the ANZCTR clinical trials database (Trial number: ACTRN12624001262594p)

Yes

10/06/2025